MAM
Geometry Encompass ropes in Ranjit Raina as CEO
MUMBAI: India’s leading experiential marketing and brand activation agency, Geometry Encompass recently announced the appointment of Ranjit Raina as the Chief Executive Officer. Raina will commence his new role from August 13, 2019. In his earlier stint with the agency, he served in the capacity of Chief Operating Officer.
Raina holds an experience of over 27 years across production houses, experiential industry and television. He first joined the agency in 2004. In his decade long stint with Encompass, he was involved with the bottom line functions primarily Finance and Corporate Operations of the organisation. He has worked with clients across sectors like Nokia, Pepsi, Hyundai, GSK, Mercedes Benz, Palmolive and Gillette. He has also played an eminent role in the acquisition of the agency by global giant WPP in 2008.
In 2014, he moved on to lead his own business venture, an engagement design consultancy company.
“Ranjit has witnessed the growth of Geometry Encompass from the very beginning and now will bring his expertise and experience back to the organization,” said Diana Cowley, CEO – APAC, Geometry Global. “The team of Geometry Encompass has always played a key part in Geometry’s Asia Pacific growth. I am confident that Ranjit will lead the team to even greater heights in the months and years to come.”
Speaking on the development, Roshan Abbas CEO and MD said, “We are happy to have Ranjit back as the leader of our team. He has proven time and again his strong understanding of the market and his expertise in live engagement experiences. He is bringing with himself the agility of a start-up and a new-age thinking that will lead Geometry Encompass to newer heights.”
Taking up the new role, Ranjit Raina said, “Geometry Encompass has always been experimental and industry-first in its approach and is driven by passionate individuals who are always working to create a new experience for brands and its consumers. Being digitally-charged and data-driven, the agency ensures best returns for its clients and the most impactful conversations with consumers. I am glad to be back with the force and hope to achieve new milestones in the near future.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
